patent.fyi
Applications  /  US 2026/0355192
United States Patent Application Publication

US 2026/0355192 A1

Published
Nov 12, 2026
Filed
Jul 27, 2023
Earliest date on the face
Jul 28, 2022
Classification
A61K 31/506
First published here
Nov 19, 2026

Generated automatically. Not reviewed by a person. Not legal advice or an opinion.

Section 1 · machine-generated

What if?

Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.

1.1Periostin transcript degradation

What ifWhat if a short interfering RNA reduces periostin production in dermal fibroblasts?
Claim language“a periostin receptor antagonist”

A lipid carrier delivers a short interfering RNA duplex to dermal fibroblasts. The guide strand directs cleavage of complementary periostin messenger RNA, reducing secretion of newly synthesized periostin.

1.1Local sensory sodium channel blockade

What ifWhat if a topical local anesthetic suppresses firing in cutaneous sensory nerves that carry itch signals?
Claim language“a periostin receptor antagonist”

A cream releases an amide local anesthetic into superficial skin. The anesthetic blocks voltage-gated sodium channels in cutaneous sensory fibers and reduces propagation of itch-related action potentials.

1.2Free compound in suspension

What ifWhat if the dichlorophenyl carboxylic acid compound is formulated without an added counterion?
Claim language“a pharmacologically acceptable salt thereof”

Micronized particles of the compound are dispersed in water with a nonionic wetting agent and a cellulose thickener. The suspension delivers a measured mass of the compound, and dissolved molecules become available to interact with the receptor.

1.2Anhydrous active in a capsule

What ifWhat if the active compound is supplied as an anhydrous, solvent-free solid?
Claim language“a hydrate or solvate thereof”

An anhydrous solid is blended with microcrystalline cellulose and filled into a hard capsule. The capsule opens in gastrointestinal fluid, which wets the powder and dissolves the active compound.

Section 2 · machine-generated

Variations

Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.

Other field of use

Canine skin explants for veterinary research

An air–liquid interface culture holds canine skin explants with the epidermis facing air and the dermis contacting culture medium. The medium contains recombinant canine periostin and one of the listed small-molecule receptor antagonists, with a vehicle-treated explant from the same specimen as a control. Histology and epidermal cytokine measurements compare tissue responses across conditions.

Component substitution

Periostin neutralization with a monoclonal antibody

A periostin-neutralizing monoclonal antibody replaces the small-molecule receptor antagonist as the active ingredient. The antibody binds extracellular periostin and reduces its interaction with cell-surface integrins. A cell adhesion assay uses periostin-coated wells to compare the antibody with a matched isotype control.

Parameter or scale variation

Concentration series for receptor antagonism assays

A 96-well plate holds periostin-coated test wells, uncoated controls and vehicle controls. Integrin-expressing cells receive an eight-point, threefold dilution series of a listed antagonist starting at 10 micromolar, with three replicate wells per concentration. After 45 minutes, a wash removes unattached cells and fluorescence imaging counts the remaining cells. A parallel viability assay measures cell survival at the same concentrations.

Combination with existing systems

Topical formulation in a diffusion cell

A vertical diffusion cell holds excised skin between a donor chamber and a stirred receiver chamber, with the epidermis facing the donor. The donor chamber holds a hydrogel containing a listed antagonist, and the receiver contains a buffered fluid selected to keep the compound in solution. Liquid chromatography measures antagonist in serial receiver samples and in an extract of the skin at the end of the run.

Skin and sensory neuron coculture

A permeable insert supports an epidermal culture above a well containing sensory neurons, with shared medium connecting the two compartments. Recombinant periostin and a listed antagonist enter the shared medium, and separate wells receive periostin with vehicle or vehicle alone. Time-lapse calcium imaging records neuronal response frequency and amplitude following treatment.

Automated or data-driven variant

Automated imaging of periostin-dependent cell adhesion

A liquid handler dispenses a listed antagonist and vehicle into periostin-coated wells and adds fluorescently labeled integrin-expressing cells. After a timed incubation and a standardized wash, an automated microscope acquires fields at fixed positions in each well. Image analysis counts labeled cells, and software normalizes counts to the vehicle wells and fits a concentration–response curve.

Specific version of a part

Extracellular periostin capture

A monoclonal antibody binds a surface on periostin involved in integrin recognition. Antibody-bound periostin has fewer accessible binding sites for engaging integrins on nearby cells.

Integrin binding site antagonist

A small molecule binds the ligand-recognition site of a periostin-binding integrin on the cell surface. Occupancy of that site reduces periostin binding and downstream integrin signaling.

Dichlorophenyl guanidinium chloride salt

The dichlorophenyl compound is formulated as a chloride salt with its guanidine group protonated. Dissolution releases the active molecular species and chloride into the aqueous phase.

Carboxyl ester prodrug

An ethyl ester masks the carboxyl group of the dichlorophenyl compound. Esterase-mediated hydrolysis releases the parent carboxylic acid and ethanol.

Section 3 · quoted from USPTO records

Other work

Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.

Document AUS 2008/0103162 A1
Published
May 1, 2008
Filed
Oct 30, 2007
Class
A61K 31/517
Document BUS 2017/0102393 A1
Published
Apr 13, 2017
Filed
May 6, 2016
Class
G01N 33/6893
Claim 1
Document A
Document B
1.1a periostin receptor antagonist as an active ingredient
An antipruritic agent comprising a nociceptine antagonist as an active ingredient.
A · US 2008/0103162 A1 · claim 1
The present invention concerns methods of assessing the effect, efficacy, safety, and/or dosing of therapeutic agents (or drug), such as integrin beta7 antagonists, for the treatment of gastrointestinal inflammatory disorders.
B · US 2017/0102393 A1 · ¶ 3
1.2wherein the antagonist is at least one compound selected from the group consisting of a compound of the following formula (I): [wherein R1 is a hydrogen atom, an alkyl group, an aryl group or an aralkyl group, each R2 is independently a hydrogen atom, an alkyl group, an aryl group or an aralkyl group, and R3 is an alkyl group, an aryl group or an aralkyl group], 3-(3,5-dichlorophenyl)-3-(2-(3-guanidinobenzamido)acetamido)propanoic acid and (S)-2-(phenylsulfonamido)-3-(4-((S)-3-((1,4,5,6-tetrahydropyrimidin-2-yl)amino)piperidin-1-yl)benzamido)propanoic acid, or a prodrug thereof, or a pharmacologically acceptable salt thereof, or a hydrate or solvate thereof.

An empty cell means only that no passage was reproduced there.

Statements in these documents
As described above, there are no satisfactory medicaments for diseases associated with itching and it is required to develop a medicament which effectively suppresses itching regardless of causative diseases from a clinical point of view.
A · US 2008/0103162 A1 · ¶ 4
As a result, they have found that a nociceptine antagonist has an antipruritic effect.
A · US 2008/0103162 A1 · ¶ 7
Additionally, the present invention provides methods of using such biomarkers to design a drug treatment and/or dosing regimen, or for prognosis.
B · US 2017/0102393 A1 · ¶ 3
Therefore, it is desirable to develop a biomarker that can accurately predict and/or track the responsiveness of a patient to treatment with a therapeutic agent.
B · US 2017/0102393 A1 · ¶ 8
Cite aspatent.fyi, US 2026/0355192 A1, claim 1, first published 2026-11-19T09:07:06-05:00, https://patent.fyi/US20260355192/, SHA-256 18043326e6ec9de5ce10fe0266e39429ca154069e514901a043a6c2225b64f63
First published
Permanent addresshttps://patent.fyi/US20260355192/
Content fingerprint (SHA-256)18043326e6ec9de5ce10fe0266e39429ca154069e514901a043a6c2225b64f63
Methodv2026-11-18.2 · automated, not reviewed by a person
Correctionscorrections@patent.fyi